희귀유전질환심포지엄조직위원회
Rare Genetic Disease Symposium Organizing Committee
PROFILE
김종민 교수
Endothelial-to-Mesenchymal Transition
: A Novel Therapeutic Target for Pulmonary Arterial Hypertension
Endothelial-to-mesenchymal transition (EndMT) contributes to pulmonary vascular remodeling and plays an important role in the pathogenesis of pulmonary arterial hypertension (PAH). Because PAH remains a fatal disease despite current treatments, targeting EndMT may provide a promising new therapeutic strategy.
숙명여자대학교 생명시스템학부
EDUCATION
2005-2009, Ph.D., Department of Molecular Biology, Dankook University, Seoul, Korea
PROFESSIONAL EXPERIENCE
2022-Present, Professor, Division of Biological Sciences, Sookmyung Women’s University, Seoul, Korea
2020-2022, Vice Dean, Research & Business Development Foundation Research Affairs, Sookmyung Women’s University, Seoul, Korea
2016-2018, Associate Dean, Research & Business Development Foundation Research Affairs, Sookmyung Women’s University, Seoul, Korea
2010-2013, Postdoctoral Associate, Yale University School of Medicine
RESEARCH ACTIVITIES & OTHERS
-
Dihydroartemisinin inhibits metastatic potential and cancer stemness by modulating the miR-200b–BMI-1/VEGF-A axis in ovarian cancer. Experimental & Molecular Medicine 2025
-
Novel biomarker discovery-coupled plasma therapy with enhanced tumor penetration for non-surgical treatment of cervical cancer. Journal of Controlled Release. 2025
-
Ratiometric Fluorophores to ONOO– in Living Cells and Monitoring Endothelial Dysfunction. Sensors and Actuators B: Chemical. 2025
-
BMPR1A Promotes ID2-ZEB1 Interaction to Suppress Excessive Endothelial to Mesenchymal Transition. Cardiovascular research. 2023
-
MicroRNA-dependent inhibition of WEE1 controls cancer stem-like characteristics and malignant behavior in ovarian cancer. Molecular Therapy-NA. 2022